In a report released today, Ritu Baral from Cowen & Co. initiated coverage with a Buy rating on Milestone Pharmaceuticals Inc (MIST) and a price target of $32. The company’s shares closed on Friday at $20.70.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.3% and a 47.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Milestone Pharmaceuticals Inc is a Moderate Buy with an average price target of $29.25, which is a 41.3% upside from current levels. In a report released today, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $26.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.13 and a one-year low of $15. Currently, Milestone Pharmaceuticals Inc has an average volume of 132.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil.
